Dr. Reddy’s Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Industry

Tom Smith

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries jointly referred to as “Dr. Reddy’s”) right now introduced the start of Sapropterin Dihydrochloride Powder for Oral Alternative, 100 mg, a therapeutic equal generic model of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 […]

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries jointly referred to as “Dr. Reddy’s”) right now introduced the start of Sapropterin Dihydrochloride Powder for Oral Alternative, 100 mg, a therapeutic equal generic model of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, authorized by the U.S. Foods and Drug Administration (USFDA).

“We are happy to launch this generic variation of Sapropterin Dihydrochloride Powder for Oral Alternative, illustrating our ongoing commitment to bring very affordable generic medicines to marketplace for sufferers,” states Marc Kikuchi, Chief Government Officer, North The usa Generics, Dr. Reddy’s Laboratories. “At the similar time, this product or service demonstrates that we are actively increasing the breadth of our portfolio with a treatment for a rare disease.”

Dr. Reddy’s Sapropterin Dihydrochloride Powder for Oral Alternative, is obtainable in 100 mg unit dose packets in a 30 depend carton.

Make sure you see the full prescribing data.
https://www.drreddys.com/pil/sapropterin_outsert_v_3.pdf

RDY-0321-334

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical organization, fully commited to offering affordable and impressive medications for healthier lives. By means of its a few organizations – Pharmaceutical Products and services & Active Ingredients, Worldwide Generics and Proprietary Goods – Dr. Reddy’s presents a portfolio of products and solutions and providers including APIs, customized pharmaceutical services, generics, biosimilars and differentiated formulations. Our big therapeutic regions of concentrate are gastrointestinal, cardiovascular, diabetology, oncology, agony administration and dermatology. Dr. Reddy’s operates in markets throughout the globe. Our key markets involve – United states of america, India, Russia & CIS countries, and Europe. For more details, log on to: www.drreddys.com

Disclaimer: This press release may well include things like statements of potential expectations and other ahead-hunting statements that are primarily based on the management’s current sights and assumptions and require recognised or unidentified risks and uncertainties that could cause genuine success, general performance or functions to vary materially from individuals expressed or implied in this kind of statements. In addition to statements which are ahead-searching by reason of context, the words “may”, “will”, “ought to”, “expects”, “strategies”, “intends”, “anticipates”, “thinks”, “estimates”, “predicts”, “likely”, or “proceed” and comparable expressions recognize ahead-searching statements. True effects, effectiveness or functions could vary materially from those in such statements thanks to devoid of limitation, (i) normal financial circumstances these types of as general performance of economical marketplaces, credit defaults, forex trade rates, fascination premiums, persistency stages and frequency / severity of insured reduction events, (ii) mortality and morbidity stages and developments, (iii) changing degrees of opposition and normal competitive factors, (iv) variations in laws and rules and in the insurance policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, together with related integration problems, and (vi) the susceptibility of our business and the markets addressed by our, and our customers’, products and providers to economic downturns as a final result of all-natural disasters, epidemics, pandemics or other common disease, like coronavirus (or COVID-19), and (vii) other dangers and uncertainties recognized in our public filings with the Securities and Exchange Commission, including people detailed less than the “Threat Factors” and “Ahead-On the lookout Statements” sections of our Once-a-year Report on Variety 20-F for the calendar year finished March 31, 2020. The company assumes no obligation to update any facts contained herein.”

Look at source variation on businesswire.com: https://www.businesswire.com/news/residence/20210407005452/en/

Contacts

Trader RELATIONS
AMIT AGARWAL
[email protected]
(PH: +91-40-49002135)

MEDIA RELATIONS
PRANAV PRIMLANI
[email protected]
(PH: +91-9381905796)

Next Post

A single Healthcare charged some individuals a charge for the COVID-19 vaccine

Health treatment corporation A single Professional medical billed administration charges to some individuals acquiring COVID-19 vaccines in Washington, DC, according to bills reviewed by The Verge. The company operates the COVID-19 vaccination site at DC’s Entertainment and Sports activities Arena. Folks vaccinated at this site were also prompted to indication […]

Subscribe US Now